|
Index of reports
> Cases resulting in death (7)
> Cases with Interstitial Lung Disease (2)
Below is the selection of adverse event reports related to Zantac (Ranitidine) that includes cases resulting in death where reactions include interstitial lung disease.
Adverse event in male receiving Zantac (Ranitidine)
Reported by a physician from Japan on 2007-10-30
Patient: male
Adverse reactions / side effects: Interstitial Lung Disease, Respiratory Failure, Lung Abscess
Adverse event resulted in: death
Suspect drug(s):
Finibax
Finibax
Indication: Lung Abscess
Norvasc
Administration route: Oral
Indication: Drug USE FOR Unknown Indication
Itraconazole
Administration route: Oral
Indication: Drug USE FOR Unknown Indication
Zantac
Administration route: Oral
Indication: Drug USE FOR Unknown Indication
Ferromia
Administration route: Oral
Indication: Drug USE FOR Unknown Indication
Erythrocin
Administration route: Oral
Indication: Drug USE FOR Unknown Indication
Biofermin R
Administration route: Oral
Indication: Drug USE FOR Unknown Indication
Sucralfate
Administration route: Oral
Indication: Drug USE FOR Unknown Indication
Slow-K
Administration route: Oral
Indication: Drug USE FOR Unknown Indication
Mucosta
Administration route: Oral
Indication: Drug USE FOR Unknown Indication
Juzen-Taiho-TO
Administration route: Oral
Indication: Drug USE FOR Unknown Indication
Other drugs received by patient: Cravit
Adverse event in male receiving Zantac (Ranitidine)
Reported by a physician from Japan on 2007-10-19
Patient: male
Adverse reactions / side effects: Interstitial Lung Disease, Lung Abscess
Adverse event resulted in: death, life threatening event
Suspect drug(s):
Finibax
Finibax
Indication: Lung Abscess
Norvasc
Administration route: Oral
Indication: Drug USE FOR Unknown Indication
Itraconazole
Administration route: Oral
Indication: Drug USE FOR Unknown Indication
Zantac
Administration route: Oral
Indication: Drug USE FOR Unknown Indication
Ferromia
Administration route: Oral
Indication: Drug USE FOR Unknown Indication
Erythrocin Lactobionate
Administration route: Oral
Indication: Drug USE FOR Unknown Indication
Biofermin R
Administration route: Oral
Indication: Drug USE FOR Unknown Indication
Sucralfate
Administration route: Oral
Indication: Drug USE FOR Unknown Indication
Slow-K
Administration route: Oral
Indication: Drug USE FOR Unknown Indication
Mucosta
Administration route: Oral
Indication: Drug USE FOR Unknown Indication
Juzen-Taiho-TO
Administration route: Oral
Indication: Drug USE FOR Unknown Indication
Other drugs received by patient: Levofloxacin
|
